Inventor · disambiguated record
Glenn Short
Also filed as: SHORT GLENN · SHORT GLENN F · SHORT III GLENN F
13 granted patents·24 pending applications·30 citations·filing 2015–2025
88Inventor score
Files withATAI Life Sciences AG16ATAI THERAPEUTICS INC11EMPATHBIO INC5DEGIACOMO MARK G2FLEX PHARMA INC2
Top patents by PatentIndex Score
37 records- 0196US12065405B2Prodrugs and conjugates of dimethyltryptamineATAI THERAPEUTICS INC·Filed 2023·Granted Aug 20, 2024·4 cites·30 claims
- 0296US11643391B2Prodrugs and conjugates of dimethyltryptamineATAI Life Sciences AG·Filed 2022·Granted May 9, 2023·7 cites·8 claims
- 0395US11602521B2N,N-dimethyltryptamine compositions and methodsATAI Life Sciences AG·Filed 2022·Granted Mar 14, 2023·6 cites·27 claims
- 0494US12012381B2Dimethyltryptamine analogues as nitric oxide delivery drugsATAI THERAPEUTICS INC·Filed 2022·Granted Jun 18, 2024·4 cites·33 claims
- 0594US11912680B2Nitric oxide releasing prodrugs of MDA and MDMAATAI Life Sciences AG·Filed 2022·Granted Feb 27, 2024·3 cites·62 claims
- 0694US11827580B2Aminotetraline activators of serotonin receptorsATAI Life Sciences AG·Filed 2022·Granted Nov 28, 2023·4 cites·58 claims
- 0791US11845736B2Prodrugs of MDMA, MDA, and derivatives thereofEMPATHBIO INC·Filed 2022·Granted Dec 19, 2023·2 cites·25 claims
- 0884US12351537B2Dimethoxyphenylalkylamine activators of serotonin receptorsATAI THERAPEUTICS INC·Filed 2024·Granted Jul 8, 2025·0 cites·11 claims
- 0980US12454516B2Nitric oxide releasing prodrugs of MDA and MDMAEMPATHBIO INC·Filed 2024·Granted Oct 28, 2025·0 cites·62 claims
- 1080US12344570B2Aminotetraline activators of serotonin receptorsATAI THERAPEUTICS INC·Filed 2023·Granted Jul 1, 2025·0 cites·18 claims
- 1179US2025282712A1Dimethoxyphenylalkylamine activators of serotonin receptorsATAI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1276US2025026731A1Prodrugs of mdma, mda, and derivatives thereofEMPATHBIO INC·Filed 2024·Application pending·0 cites
- 1375US2025282708A1Aminotetraline activators of serotonin receptorsATAI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1472US2023041584A1Novel prodrugs and conjugates of dimethyltryptamineATAI Life Sciences AG·Filed 2022·Application pending·0 cites
- 1568US2025205191A1R(-)-mdma compositions and methods of treatmentEMPATHBIO INC·Filed 2024·Application pending·0 cites
- 1667US11926574B2Dimethoxyphenylalkylamine activators of serotonin receptorsENTHEOGENIX BIOSCIENCES INC·Filed 2022·Granted Mar 12, 2024·0 cites·21 claims
- 1767US2025152553A1Carbamothioate, and carbamodithioate derivatives of mdma, mda or its optically active (r)- or (s)-mdma and mda isomersEMPATHBIO INC·Filed 2024·Application pending·0 cites
- 1867US2024408054A1Compositions and methods for increasing exposure of r(-)-mdaATAI Life Sciences AG·Filed 2024·Application pending·0 cites
- 1967US2025197395A1Ibogaine and noribogaine analogs and uses thereofATAI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2066US12343319B2Compositions and methods for treatment of diseases and disordersATAI THERAPEUTICS INC·Filed 2024·Granted Jul 1, 2025·0 cites·13 claims
- 2166US2024366542A1Sulfoximine activators of serotonin receptorsATAI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2266US2024425470A1Substituted benzofuran propyl amine modulators of monoaminergic transportersATAI Life Sciences AG·Filed 2024·Application pending·0 cites
- 2365US2024376116A1Ibogaine and noribogaine analogs and methods of useATAI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2464US2023097530A1Enantiomeric ratios of 3,4-methylenedioxymethamphetamine and related metabolites and uses thereofATAI Life Sciences AG·Filed 2022·Application pending·0 cites
- 2564US2023129723A1Enantiomeric ratios of 3,4-methylenedioxymethamphetamine and related metabolites and uses thereofATAI Life Sciences AG·Filed 2022·Application pending·0 cites
- 2663US11236078B2Heterocyclic inhibitors of the sodium channelDEGIACOMO MARK G·Filed 2019·Granted Feb 1, 2022·0 cites·2 claims
- 2763US2024116896A1Heteroatom substituted cyclic and alkyl amines as activators of serotonin receptorsATAI Life Sciences AG·Filed 2023·Application pending·0 cites
- 2862US2024082212A1Use of mdma for treatment of stress-related disordersATAI Life Sciences AG·Filed 2023·Application pending·0 cites
- 2961US2023024991A1Prodrugs of acyl carnitinesATAI Life Sciences AG·Filed 2022·Application pending·0 cites
- 3061US2023310374A1Compositions and methods for treating headache or facial painATAI Life Sciences AG·Filed 2023·Application pending·0 cites
- 3158US2025268846A1Compositions and methods for treatment of diseases and disordersATAI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3257US2023100844A1Ibogaine combination treatmentATAI Life Sciences AG·Filed 2022·Application pending·0 cites
- 3357US2023099972A1Compositions and methods for treating headachesATAI Life Sciences AG·Filed 2022·Application pending·0 cites
- 3457US2023270714A1Salvinorin compositionsATAI Life Sciences AG·Filed 2022·Application pending·0 cites
- 3548US2017145003A1Heterocyclic inhibitors of the sodium channelDEGIACOMO MARK G·Filed 2015·Application pending·0 cites
- 3643US2019038573A1Ion channel activators and methods of useFLEX PHARMA INC·Filed 2018·Application pending·0 cites
- 3734US2017042834A1Ion channel activators and methods of useFLEX PHARMA INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Glenn Short files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →